scispace - formally typeset
O

Ola Blennow

Researcher at Karolinska University Hospital

Publications -  56
Citations -  1204

Ola Blennow is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 12, co-authored 24 publications receiving 636 citations. Previous affiliations of Ola Blennow include Karolinska Institutet.

Papers
More filters
Journal ArticleDOI

Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.

Michael Uhlin, +9 more
- 01 Feb 2014 - 
TL;DR: The study identifies patients at risk of post-transplant lymphoproliferative disease after transplantation in need of pre-emptive measures and identifies patients with long-term survival problems despite initial successful treatment.
Journal ArticleDOI

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).

Livio Pagano, +119 more
- 14 Oct 2021 - 
TL;DR: In this paper, the authors studied the risk factors for adverse outcomes in patients with hematological malignancies (HM) who developed COVID-19 and analyzed predictors of mortality.
Journal ArticleDOI

Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study

Mats Remberger, +37 more
- 01 Nov 2011 - 
TL;DR: Overall survival (OS) and transplant-related mortality (TRM) improved significantly in the more recent periods, with the best results during the last period (2006-2009) and a 100-day TRM of 5.5%.
Journal ArticleDOI

Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.

Peter Bergman, +43 more
- 01 Dec 2021 - 
TL;DR: In this paper, the authors investigated safety and efficacy of BNT162b2 mRNA vaccination in five selected groups of immunocompromised patients and healthy controls and found that the vaccine was safe.
Journal ArticleDOI

Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations.

Ola Blennow, +7 more
- 01 Feb 2014 - 
TL;DR: Bloodstream infection after allogeneic hematopoietic stem cell transplantation (HSCT) is a well‐known complication during the pre‐engraftment phase and knowledge of trends in etiology and antibiotic susceptibility of BSI is important as the time to effective antibiotic treatment is closely associated with survival in bacteremic patients with septic shock.